![](/wp-content/uploads/2019/09/easd-announcement.png)
$599
EASD 2022 Key Press Releases (Sept 22)
On the fourth day of EASD 2022, three key news items were observed from Novo Nordisk, Merck, and Better Therapeutics. Separately, it has been observed that the start date has been delayed for Novo’s first cagrisema Ph3 pivotal trial (Ph3 REDEFINE-2). Below FENIX provides insights and context for the respective announcements.